Hopstem Biotechnology Received FDA Clearance of IND Application for hNPC01 in Chronic Ischemic Stroke

The iPSC-derived Human Forebrain Neural Progenitor Cell Injection hNPC01 of Hopstem has Received CDE's Clinical Implication Approval

The launch meeting of the clinical research project of Hopstem hNPC01 universal cell therapy product for the treatment of stroke sequelae was successfully held.

Good news! Hopstem has been awarded as one of the "Top 10 Organoid Enterprises with the Most Investment Value"!

Hopstem has honored to list on the “2023 Top 100 Future Healthcare List”